Medicare’s coverage of GLP-1 weight loss drugs is about to change in a big way. On July 1, 2026 the Centers for Medicare & Medicaid Services will start the Medicare GLP-1 Bridge —which will give eligible Part D beneficiaries access to Wegovy, Zepbound, and Foundayo for a $50 monthly copay. The Bridge runs through December 31, 2027 and serves as a transition to a longer term Medicare obesity care program called BALANCE. Here’s what Medicare Part D beneficiaries need to know.
NOTE: This is an informational article. DO NOT CALL SENIOR65.com FOR ASSISTANCE WITH WEIGHT LOSS DRUGS. Call your Part D drug provider or 1-800-633-4227 to speak to Medicare directly.
What is the Medicare GLP-1 Bridge?
The GLP-1 Bridge is a CMS demonstration program — not a permanent expansion of Part D. It operates outside the standard Part D benefit, with Humana acting as the central processor handling prior authorizations and pharmacy payments nationwide.
Key facts:
- Launch date: July 1, 2026
- End date: December 31, 2027
- Drugs covered: Wegovy (all formulations), Zepbound (KwikPen formulation only), and Foundayo
- Beneficiary cost: $50 copay per monthly supply
- Available nationwide in all states and U.S. territories
Source: CMS.gov — Medicare GLP-1 Bridge.
Who Is Eligible for the GLP-1 Bridge?
To qualify, a beneficiary must be enrolled in a Medicare Part D plan — either a standalone prescription drug plan (PDP) or a Medicare Advantage plan that includes Part D (MA-PD). A medical provider must submit a prior authorization request attesting that the beneficiary meets one of these clinical criteria:
- BMI ≥ 35 at the time GLP-1 therapy was initiated, or
- BMI ≥ 30 plus one of: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or higher, or
- BMI ≥ 27 plus one of: pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease
The prescription must also be paired with structured lifestyle modification — nutrition and physical activity guidance consistent with the FDA-approved label. CMS will release more detail on the prior authorization process in Spring 2026.
How the $50 Copay Works
Through the Bridge, participating manufacturers will provide eligible drugs at a net price of $245 per monthly supply. Eligible beneficiaries pay a flat $50 copay regardless of which phase of the Part D benefit they’re in.
Important: the $50 copay does not count toward your Part D out-of-pocket cap of $2,100, and the Bridge drug cost does not count toward your Part D covered drug costs. The Bridge runs on its own track separate from Part D. Coupons and discount programs cannot be applied to Bridge claims.
What Does Part D Still Covers Under the Standard Benefit?
The Bridge is for weight-management uses only. The standard Part D benefit still applies in three important cases:
- Ozempic and Mounjaro for Type 2 diabetes remain covered under Part D (subject to plan formulary and prior authorization).
- Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight is coverable under Part D formularies (plan-discretionary, prior authorization required). This is based on the FDA’s March 2024 approval following the SELECT clinical trial.
- Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity is coverable under Part D formularies (plan-discretionary, prior authorization required).
If your prescription qualifies for coverage under standard Part D, your plan should run it through the regular benefit — not the Bridge. For full eligibility and program details, see CMS.gov.
What to Do If You Think You Qualify
If you’re prescribed Wegovy, Zepbound, or Foundayo for weight management — or you’ve been wanting to talk to your doctor about a GLP-1 medication — here are you next steps.
- Confirm you’re enrolled in a Part D plan (standalone PDP or MA-PD).
- Talk to your doctor about whether you meet the Bridge’s clinical criteria — your BMI, any qualifying conditions, and a lifestyle-modification plan.
- If you qualify, your provider submits the prior authorization request to the Bridge’s central processor (Humana). CMS will release the exact process in Spring 2026.
- Once approved, fill the prescription at a participating pharmacy and pay the $50 copay.
NOTE: DO NOT CALL SENIOR65 FOR ASSISTANCE WITH WEIGHT LOSS DRUGS. Call your Part D drug provider or 1-800-633-4227 to speak to CMS directly.
FAQs: Medicare GLP-1 Bridge
Q: Does Medicare cover Wegovy?
A: Yes, in two ways. Starting July 1, 2026, eligible Part D beneficiaries can get Wegovy for weight management through the Medicare GLP-1 Bridge for a $50 monthly copay. Wegovy is also coverable under standard Part D when prescribed for cardiovascular risk reduction in adults with established cardiovascular disease.
Q: Does Medicare cover Ozempic?
A: Yes, under standard Part D, when prescribed for Type 2 diabetes management. Prior authorization is nearly universal, and coverage details vary by plan formulary.
Q: Does Medicare cover Zepbound?
A: Yes, in two ways. The KwikPen formulation is available through the new GLP-1 Bridge for weight management starting July 1, 2026, for a $50 copay. Zepbound is also coverable under standard Part D when prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity.
Q: Does the $50 Bridge copay count toward my Part D out-of-pocket cap?
A: No. The Bridge operates outside the Part D payment flow, so neither the $50 copay nor the manufacturer’s $245 net cost counts toward your Part D out-of-pocket maximum of $2,100. The $50 copay also stays the same regardless of which phase of the Part D benefit you’re in.
Q: Do I need to switch Part D plans to use the Bridge?
A: No. The Bridge is available nationwide to anyone enrolled in any Part D plan (PDP or MA-PD) who meets the clinical criteria. Your plan does not have to opt in.
Q: What happens after the Bridge ends in December 2027?
A: CMS plans to transition to a longer-term program called the BALANCE Model. The Bridge was extended to December 31, 2027 in part to give CMS more time to develop the next phase. For the latest, check CMS.gov.
Please direct all questions to your Part D provider or CMS directly at 1-800-633-4227. We cannot assist you with weight loss drugs. If you have questions about Medigap only, please contact Senior65.com